Lewandowski, K.C.; Kawalec, J.; Kusiński, M.; Dąbrowska, K.; Matusiak, A.E.; Dudek, I.; Lewiński, A.
The Utility of Intravenous Methylprednisolone as an Adjunct Treatment for Drug-Resistant Amiodarone-Induced Thyrotoxicosis. J. Clin. Med. 2024, 13, 324.
https://doi.org/10.3390/jcm13020324
AMA Style
Lewandowski KC, Kawalec J, Kusiński M, Dąbrowska K, Matusiak AE, Dudek I, Lewiński A.
The Utility of Intravenous Methylprednisolone as an Adjunct Treatment for Drug-Resistant Amiodarone-Induced Thyrotoxicosis. Journal of Clinical Medicine. 2024; 13(2):324.
https://doi.org/10.3390/jcm13020324
Chicago/Turabian Style
Lewandowski, Krzysztof Cezary, Joanna Kawalec, Michał Kusiński, Katarzyna Dąbrowska, Aleksandra Ewa Matusiak, Iga Dudek, and Andrzej Lewiński.
2024. "The Utility of Intravenous Methylprednisolone as an Adjunct Treatment for Drug-Resistant Amiodarone-Induced Thyrotoxicosis" Journal of Clinical Medicine 13, no. 2: 324.
https://doi.org/10.3390/jcm13020324
APA Style
Lewandowski, K. C., Kawalec, J., Kusiński, M., Dąbrowska, K., Matusiak, A. E., Dudek, I., & Lewiński, A.
(2024). The Utility of Intravenous Methylprednisolone as an Adjunct Treatment for Drug-Resistant Amiodarone-Induced Thyrotoxicosis. Journal of Clinical Medicine, 13(2), 324.
https://doi.org/10.3390/jcm13020324
